Find a Physician | How to Contribute | About Us | Clinical Trials
 
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Gynecological

A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination with Epacadostat in Adults with Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

The study will test two cancer drugs, CRS-207 and epacadostat. The purpose of this research study is to determine whether the study drug, CRS-207, alone or in combination with epacadostat, is safe and effective in women with platinum–resistant ovarian, fallopian, or peritoneal cancer. Another purpose of the study is to find out what the best dose of epacadostat is.

Status: Accepting New Patients
Principal Investigator: Daniela Matei

An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer

The purpose of this study is to look at how patients respond to treatment with guadecitabine and pembrolizumab. The researchers will also be looking at the amount of time it takes for cancer to get worse when participants take the study drugs.

Status: Accepting New Patients
Principal Investigator: Daniela Matei

A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVa, Stage IVb, or Recurrent Endometrial Cancer

The purpose of this study is to determine if the drug combination of paclitaxel, carboplatin, and metformin works better than paclitaxel and carboplatin alone in treating stage III, IVA, IVB or recurrent endometrial cancer and to determine what side effects are caused by these drugs.

Status: Accepting New Patients
Principal Investigator: Shohreh Shahabi

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

To determine the clinical activity of tivozanib in patients with platinum-resistant, recurrent ovarian, fallopian tube or primary peritoneal cancer.

Status: Accepting New Patients
Principal Investigator: Mario Pineda

A Phase 1 Study Of COTI-2 For The Treatment Of Advanced Or Recurrent Gynecologic Malignancies

The main purpose of this study is to learn about and compare the highest tolerable doses of the drug COTI-2 that can be given to patients with advanced or recurrent endometrial, ovarian, primary peritoneal, or fallopian tube cancer.

Status: Accepting New Patients
Principal Investigator: Wilberto Nieves-Neira

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This purpose of this study is to determine the safety and effectiveness of a drug called tazemetostat to treat cancer

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

The purpose of this study is to determine if a change in diet and exercise in women with ovarian, fallopian tube, or primary peritoneal cancer, has an effect on the length of time patients are cancer-free following initial treatment.

Status: Accepting New Patients
Principal Investigator: Shohreh Shahabi

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

The purpose of this study is to compare the effects, good and/or bad, of giving additional chemotherapy to patients after the usual treatment of chemotherapy and radiation for cervical cancer.

Status: Accepting New Patients
Principal Investigator: Eric Donnelly

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone (ANZGOG 0902/GOG-0274/RTOG 1174)

The purpose of this study is to compare standard treatment, radiation therapy combined with the chemotherapy drug cisplatin (chemo-radiation), to standard chemo-radiation therapy plus additional experimental chemotherapy with FDA approved agents carboplatin and paclitaxel to see if it reduces risk of tumor recurrence and improves overall survival.

Status: Accepting New Patients
Principal Investigator: Eric Donnelly

last updated: Tue - May 23, 2017 - 06:40 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.